Blood Screening Market is Expected To Observe Upward Trajectory During 2021-2026

Posted by aartimurkute on January 13th, 2022

Soaring instances of infectious diseases remain the prime factor fuelling demand for the various blood screening procedures, and products worldwide. As the world sees expanding elderly population, the risk of their susceptibility to a range of chronic health conditions also tends to increase. Fairfield Market Research in its new study sheds light on how the performance of global blood screening market is unfolding as it garners greater traction in the field of diagnostics. The role of blood donation programmes, and blood transfusion initiatives are expected to remain instrumental to the market build-up, says research. The report states that the COVID-19 pandemic brought in a slew of opportunities to the market.

To Read Complete Report of Blood Screening Market: https://www.fairfieldmarketresearch.com/report/blood-screening-market

Reagents and Kits Retain their Dominance over Other Categories in Blood Screening Market

Demand for blood screening products, and procedures is likely to remain high at hospitals. However, blood banks are likely to be the top end user segment in global blood screening market as indicated by the preliminary findings of research. The report also points to continued dominance of blood screening kits and reagents over all other product and service categories. Apart from their wide availability, and easy accessibility on the market, sales of blood screening kits and reagents are expected to soar with the growing demand for faster, more dependable, and specific detection of TTIs, i.e., a variety of transfusion transmissible infections. With the growing number of blood donation and transfusion initiatives are the associated tests, these reagents and kits will continue to witness incessant demand.

Technological Advancements to Uphold Market Performance

Advent of technology involved in a range of tests recommended during pregnancy for detection of potential prenatal abnormalities also will be responsible for driving demand for blood screening procedures, and products. The importance of next generation sequencing (NGS), western blot assay, and enzyme linked immunosorbent assay (ELISA) has been on the rise, which again is a string indication of the flourishing future of blood screening market. Emergence of microbiological screening and multiplexing technology for HBV, HCV, HIV, and pathogen reduction would further strengthen the adoption potential of blood screening. A spectrum of viral infectious disease agents like hepatitis, HIV-1 and -2, and HTLV can only be detected through blood screening, which continues to create a steady stream of demand supporting the growth of blood screening market. With higher sensitivity, and specificity for viral nucleic acid, nucleic acid amplification test (NAT) is likely to remain the most preferred blood screening technology, projects the report.

North America, and Europe to Remain the Prime Markets for Providers of Blood Screening Products, and Procedures

Besides the highest prevalence of chronic disease conditions, and remarkably high prevalence of infectious diseases, the market for blood screening procedures, and products in North America will also benefit from the escalating pace of blood donation initiatives. The region also continues to receive a boost from the sophisticated healthcare and medical infrastructure, as well as favourable reimbursement scenario. Notable expansion of the diagnostics sector is expected to remain one of the most important factors fostering the growth of blood screening market, especially in the US. European markets are likely to gain support from the regulatory environment.

On the other hand, demand for blood screening across Asia Pacific is expected to rise as a result of increasing significance of blood screening tests in the field of diagnostics. In addition to an ascending number of blood donation, and transfusion initiatives, soaring public awareness about the potential impacts of disease transmission during the process of blood transfusion will also favour the growth of blood screening market across Asia Pacific. The market in this region will however continue to face the challenges thrown by the lack of standardisation associated with all kinds of blood transfusion procedures.